Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo. The company also announced a dividend for the first time.

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

impacting the company's revenue and profit margins. Despite these challenges, Regeneron's other drugs, particularly Dupixent and Libtayo, show promise for future growth and revenue generation.

The EC approved Libtayo – a fully human monoclonal antibody ... therapeutics for the treatment of cancer. Meanwhile, another company focused on advanced cervical cancer is Nykode Therapeutics ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...

Libtayo was first approved in 2018 ... This is an increase from the ORR of 29% the company shared in May and includes two responses that were confirmed after an initial data analysis.

Valued at $73.8 billion by market cap, the company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. Companies worth $ ...

The company utilizes proprietary technologies like VelociSuite, to produce optimized human antibodies and bispecific antibodies. Its marketed products include EYLEA, Dupixent, Libtayo, Kevzara ...